Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Assets: 2010-2025

Historic Current Assets for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $42.3 million.

  • Lineage Cell Therapeutics' Current Assets rose 22.85% to $42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.3 million, marking a year-over-year increase of 22.85%. This contributed to the annual value of $51.0 million for FY2024, which is 32.66% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Current Assets is $42.3 million, which was down 3.61% from $43.8 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Current Assets peaked at $111.5 million during Q4 2021, and registered a low of $34.4 million during Q3 2024.
  • Its 3-year average for Current Assets is $44.3 million, with a median of $43.8 million in 2025.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Current Assets surged by 153.53% in 2021, and later tumbled by 46.21% in 2022.
  • Lineage Cell Therapeutics' Current Assets (Quarterly) stood at $111.5 million in 2021, then tumbled by 46.21% to $60.0 million in 2022, then plummeted by 35.93% to $38.4 million in 2023, then surged by 32.66% to $51.0 million in 2024, then grew by 22.85% to $42.3 million in 2025.
  • Its Current Assets stands at $42.3 million for Q3 2025, versus $43.8 million for Q2 2025 and $50.0 million for Q1 2025.